Remicade pushes Mitsubishi Tanabe to growth
This article was originally published in Scrip
Executive Summary
Continued strong growth for Remicade (infliximab) offset weakness elsewhere in Mitsubishi Tanabe Pharma's (MTP) portfolio in the nine months to December 31st, nudging overall group revenues into positive territory.